证券日报网讯1月26日，三生国健发布公告称，公司2025年度预计实现营业收入42.00亿元左右，与上年 同期相比，将增加30.06亿元左右，相比上年涨幅约251.76%。 ...

格隆汇1月26日丨特宝生物(688278.SH)公布向不特定对象发行可转换公司债券预案，本次发行可转债募 集资金总额（含发行费用）不超过人民币15.33亿元（含本数），扣除发行费用后的募集资金净额将用 于以下项目：新药研发项目、生物技术创新融合中心建设项目、特宝生物创新药物生产改扩项目-产线 建设。 ...

格隆汇1月26日｜据港交所文件，北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

据港交所文件：北京百普赛斯生物科技股份有限公司向港交所提交上市申请书。 ...

Core Viewpoint - Frontline Bio's FB7013 is the world's first clinical candidate targeting the key protein MASP-2 via siRNA, showing significant potential as a First-in-Class drug [1] Group 1: Drug Efficacy and Safety - Preclinical data indicates that a single subcutaneous injection in healthy crab-eating macaques resulted in over 95% reduction of serum MASP-2 protein, with effects lasting over 105 days [1] - In an IgA nephropathy model in crab-eating macaques, FB7013 demonstrated a dose-dependent improvement in key metrics such as urine total protein to creatinine ratio (uPCR), urine total protein (uTP), and estimated glomerular filtration rate (eGFR) [1] - After 8 weeks of high-dose treatment, there was a 43% reduction in glomerular IgA deposits and a 36% decrease in mesangial cell numbers, with off-target analysis showing no significant off-target risks, indicating good safety [1] Group 2: Clinical Development and Regulatory Status - As of the end of 2025, the company has submitted an IND application for FB7013 to the National Medical Products Administration, which has been accepted, marking the drug's entry into the clinical application approval process [1] Group 3: Business Development and Collaboration - The company maintains an open attitude towards business development collaborations and actively explores opportunities that align with its product development strategy [1]

Core Viewpoint - Tonghua Dongbao is expected to achieve a significant turnaround in its financial performance for 2025, with a projected net profit of approximately 1.242 billion yuan and a net profit excluding non-recurring gains of about 402 million yuan, both showing a substantial recovery compared to the previous year [1] Group 1: Performance Highlights - The company's insulin analog products are experiencing rapid growth, with sales increasing by over 100% year-on-year, becoming the main driver of revenue growth [2] - In Q3 2025, revenue from insulin analogs surpassed that of traditional human insulin, marking a key milestone in product upgrade [2] - Tonghua Dongbao's market share in the insulin sector remains second in the industry, with human insulin market share rising to 45.5%, maintaining the leading position domestically [2] Group 2: R&D Progress - The company is increasing R&D investment, advancing multiple innovative drug projects in the metabolic disease field [3] - Significant progress has been made with GLP-1 drugs, including the completion of Phase III clinical trials for semaglutide and positive results from Ib phase trials for a GLP-1/GIP dual-target agonist [3] - The company is also accelerating the development of insulin combination formulations and has received marketing approval for a gout drug, showcasing a diversified pipeline [3] Group 3: International Expansion - Tonghua Dongbao's internationalization has accelerated, with several core products achieving registration and market access breakthroughs in emerging markets [4] - The company is implementing a dual-output model of "raw materials + formulations," with significant progress in the internationalization of insulin analogs and human insulin [4] - The strategy includes breakthroughs in mature markets and rapid access in emerging markets, gradually building a sales network across multiple regions [4] Group 4: Shareholder Returns and Talent Incentives - The controlling shareholder, Dongbao Industrial Group, has increased its stake by 228 million yuan, reflecting confidence in the company's future [5] - The company plans to repurchase shares worth 20 to 40 million yuan for employee stock ownership or equity incentives, aiming to align interests among shareholders, the company, and employees [6] Group 5: Value Reassessment - Experts believe that as the revenue share of insulin analogs continues to rise, Tonghua Dongbao's profit structure and growth quality are expected to improve further [7] - The company is constructing a new growth pattern through the volume increase of insulin analogs, gradual realization of innovative drugs, and accelerated internationalization [7]

Core Insights - The Bioeconomy Index (970038) closed at 2278.54 points, reflecting a 0.57% increase with a trading volume of 40.686 billion yuan and a turnover rate of 3.97% [1] - Among the constituent stocks, 27 companies experienced an increase, with Hualan Biologicals leading with a 20.0% rise, while 23 companies saw a decline, with Meihua Medical leading the drop at 5.46% [1] Fund Flow Analysis - The net inflow of main funds into the Bioeconomy Index constituents totaled 804 million yuan, while speculative funds saw a net inflow of 89.0137 million yuan, and retail investors experienced a net outflow of 893 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Group 1 - Capbio experienced a 20% limit-up increase, indicating strong market performance [1] - Zhifei Biological and Wanfu Biological both saw increases exceeding 10%, reflecting positive investor sentiment [1] - Zhijiang Biological and Hualan Vaccine previously reached limit-up, showcasing significant market interest [1] Group 2 - Companies such as CanSino, Shuoshi Biological, and Kehua Biological also reported notable gains, indicating a broader trend in the sector [1]

医药股，集体异动！ 今日（1月26日）午后，医药股大幅走强，生物疫苗、体外诊断、肝炎等方向领涨。其中，凯普生物直线拉升 至20%涨停，用时不足1分钟；海王生物、科华生物等股票也陆续涨停。 印度突然出现尼帕病毒疫情，截至目前，印度已有5例确诊病例，其中包括医护人员。这一消息可能刺激了医 药股的上涨。另外，年初多个创新药BD交易落地，中国创新药出海趋势向好。有券商研究机构表示，随着更 多国产创新药的出海、医保谈判的常态化以及产业链的成熟，创新药赛道有望持续成为资金配置的核心方向。 医药股异动 午后，医药股突然拉升，凯普生物直线涨停，海王生物、科华生物、迈克生物、金迪克等股票也陆续封死涨停 板。此前，华兰疫苗、鲁抗医药、达安基因等个股已涨停。截至下午收盘，生物疫苗、流感指数涨幅超过 3%，体外诊断、肝炎指数涨超2%。 | (分时 1分钟 更多) | | 壳价 叠加 重播 统计 | 画线 F10 标记 -自选 返回 | | 凯普生物 300639 R | | 医疗保健 | | --- | --- | --- | --- | --- | --- | --- | --- | | 7.25 | 凯普生物 分时 成交量 | ...

Core Viewpoint - Microchip Biotech (688321.SH) is expected to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the same period last year, thus turning a profit [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, representing a year-on-year increase of about 168.03 million yuan, indicating a turnaround from loss to profit [1] - The company's revenue is expected to grow significantly, driven by the sales of its product, Siglecatin Sodium, which has seen a year-on-year increase of around 123% due to its unique clinical value and effective commercialization strategies [1] Group 2: Product Development and Market Recognition - The product, Sidabamine, has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025 [1] - The inclusion of Sidabamine in the latest version of the National Medical Insurance Directory under regular Class B management in December 2025 is expected to contribute to a year-on-year revenue growth of approximately 16% [1]